Pharma's Stake In Essential Health Benefits
This article was originally published in RPM Report
Executive Summary
The health reform law lists prescription drugs as one of the 10 categories that plans must include as essential benefits. Decisions on which medicines, how many, and, perhaps most importantly, at what cost to the patient are all questions that HHS needs to determine.
You may also be interested in...
Health Care Reform's Pricing Impact: 340B Purchasers See Initial 10% Decline in Brand Prices
How big an impact do the new Medicaid rebate rules have on prices? There's now way to tell for sure, but prices files analyzed for the 340B program offer a pretty good clue.
Health Care Reform and the Biopharma Sector: A Complete Tactical Victory
The health care reform debate was wild and wooly-but it is hard to imagine a better outcome for the biopharma sector in general and the Pharmaceutical Research & Manufacturers of America in particular. So why isn't anybody celebrating?
Health Care Reform: For Biopharmas There Is Much To Like
The passage of health reform was a momentous juncture for the health care industry, but is also just the beginning of years of policy development that amend or define the crucial details of the 2010 proposals. Analysts are still tallying the reform bill's final cost to biopharma companies; even so, the industry stands to gain more it gives up with the landmark legislation's passing.